Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.

A new cervical cancer treatment is showing promise in boosting survival rates and reducing recurrence What this breakthrough means for patients.

Cervical cancer, caused by Human Papilloma Virus (HPV), is not hereditary, and HPV infection doesn't always lead to cancer. Pap smears are crucial for early detection, and HPV vaccines can prevent ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

This guest essay reflects the views of Dr. Richard Barakat, physician-in-chief at the Northwell Health Cancer Institute.